PDRN for Eczema & Atopic Dermatitis: How It Works & Evidence

How PDRN Targets Eczema

PDRN addresses eczema through several interconnected mechanisms that target both the inflammatory and barrier-dysfunction components of the disease. First, A2A receptor activation on immune cells (T lymphocytes, mast cells, macrophages) suppresses the Th2 cytokine cascade — IL-4 and IL-13 (which drive IgE overproduction and further barrier gene downregulation), IL-31 (the primary pruritogenic cytokine responsible for the intense itch of eczema), and TNF-alpha (which amplifies the inflammatory milieu and drives epidermal spongiosis). This cytokine suppression directly reduces flare severity, pruritus intensity, and the itch-scratch cycle that perpetuates AD chronicity. Second, A2A receptor engagement on mast cells stabilizes these cells against degranulation, reducing histamine and tryptase release that contribute to acute itch and vascular permeability in eczema lesions. Third, PDRN's nucleotide salvage pathway activity provides deoxyribonucleotide substrates that support normalized keratinocyte differentiation — restoring ceramide synthesis, filaggrin expression, and the organized lipid lamellae of the stratum corneum that constitute a functional permeability barrier. Fourth, PDRN promotes healthy dermal microcirculation through VEGF-mediated angiogenesis, ensuring adequate nutrient delivery to the metabolically stressed epidermis. Together, these mechanisms break the inflammation-barrier damage cycle at multiple points simultaneously, offering a more comprehensive approach than agents targeting only one arm of AD pathology.

PDRN (polydeoxyribonucleotide) has emerged as a compelling candidate for eczema management due to its dual mechanism of action that directly addresses both pillars of AD pathology. Through specific binding to the adenosine A2A receptor, PDRN activates the adenylate cyclase-cAMP-PKA signaling cascade, which inhibits NF-kB nuclear translocation and suppresses transcription of the Th2 cytokines central to eczema flares — including IL-4, IL-13, IL-31, and TNF-alpha. This anti-inflammatory pathway is pharmacologically distinct from corticosteroids and calcineurin inhibitors, suggesting potential for complementary or adjunctive use without compounding their side effect profiles.

Beyond cytokine suppression, PDRN supports eczema-affected skin through the nucleotide salvage pathway — an independent mechanism in which PDRN is enzymatically degraded to individual deoxyribonucleotides that provide substrates for DNA synthesis in rapidly proliferating keratinocytes. In eczema, epidermal turnover is accelerated and keratinocyte differentiation is disordered, contributing to the characteristic barrier deficiency. By supplying nucleotide building blocks, PDRN supports normalized keratinocyte proliferation and terminal differentiation, promoting proper filaggrin expression and lamellar body formation — the structural elements that restore barrier competence and reduce TEWL.

A 2020 preclinical study by Irrera et al. published in Biomedicines demonstrated that PDRN significantly reduces clinical severity scores, scratching behavior, epidermal hyperplasia, and mast cell infiltration in a DNCB-induced mouse model of atopic dermatitis, with effects confirmed to be mediated through the A2A receptor using the selective antagonist ZM241385. While translation from murine models to human clinical practice requires further investigation, these findings establish a strong biological rationale for PDRN as a potential adjunctive therapy in eczema management — particularly for patients seeking non-steroidal options for maintenance care and flare prevention.